Aug 16, 2024
A year after rejecting it, the FDA has now approved Ascendis Pharma’s once-daily injectable YORVIPATH for hypoparathyroidism treatment. Ascendis Pharma’s YORVIPATH (palopegteriparatide), formerly called TransCon PTH, has been approved for the treatment of adults with hypoparathyroidism. This rare condition, charact...
Read More...
Sep 25, 2019
Hypoparathyroidism is a rare endocrine condition marked by low-calcium and high-phosphate levels as compared to a normally lower or inappropriate level of normal Parathyroid hormone (PTH). Understanding of the Hypoparathyroidism epidemiological data become difficult, considering that the country-specific data i...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper